What is the role of dividends in Christopher Reidy’s Encompass Health (EHC) share awards?

A $0.19 per share dividend paid on April 15, 2026 generated additional restricted stock units and reinvested shares for Reidy. The number of units and shares credited depends on existing balances and the $105.24 closing price used to calculate dividend-related awards.

Director Christopher Reidy of Encompass Health (EHC) gains shares via awards and dividend plans

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Encompass Health Corp director Christopher R. Reidy increased his direct holdings through routine equity compensation events. On April 16, 2026, he acquired 334 shares of Encompass Health Common Stock at a weighted average of $106.48 per share as a grant or award. On April 15, 2026, he also acquired 19 shares at $0.00 per share through a directors’ deferred stock investment plan and dividend reinvestment tied to a $0.19 per share dividend and a $105.24 closing price. Following these transactions, he directly holds 15,803 shares of Encompass Health Common Stock.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Reidy Christopher R

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Encompass Health Common Stock	334	$106.48	$36K
Grant/Award	Encompass Health Common Stock	19	$0.00	--

Holdings After Transaction: Encompass Health Common Stock — 15,803 shares (Direct)

Footnotes (1)

Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments, The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On April 15, 2026, Encompass Health paid a dividend on its common stock of $0.19 per share and the closing price was $105.24. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment. The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2025 to defer fixed percentages of their director fees for 2026. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the director's fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. The number reported represents shares purchased with the quarterly fee deferral and the dividend of $0.19 per share paid on April 15, 2026. This per share price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $106.21 to $106.48, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.

Key Figures

Awarded shares: 334 shares Weighted average price: $106.48 per share Deferred/plan shares: 19 shares +4 more

7 metrics

Awarded shares 334 shares Grant/award acquisition on April 16, 2026

Weighted average price $106.48 per share Price for 334 awarded shares

Deferred/plan shares 19 shares Grant/award acquisition on April 15, 2026 at $0.00

Shares held after transactions 15,803 shares Total direct Encompass Health Common Stock

Dividend per share $0.19 per share Dividend paid on April 15, 2026

Dividend day closing price $105.24 per share Used to calculate RSUs credited on dividend

Purchase price range $106.21–$106.48 per share Range for multiple transactions included in weighted average

Key Terms

restricted stock units, non-qualified deferral plan, dividend reinvestment, weighted average price

4 terms

restricted stock units financial

"additional restricted stock units ("RSUs") are credited to each non-employee director's account"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

non-qualified deferral plan financial

"The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan"

dividend reinvestment financial

"such stock is entitled to cash dividends that are reinvested by the Plan administrator"

Dividend reinvestment is when the money earned from a company's profit sharing, called dividends, is automatically used to buy more shares of that company instead of being received as cash. This process helps investors grow their holdings over time without extra effort, much like using earned interest to buy more of a savings account. It encourages long-term investment growth by continuously increasing the amount of shares owned.

weighted average price financial

"This per share price is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Form 4 Insider Transactions: What Each Field Means →

04/16/2026 - 02:42 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Reidy Christopher R

(Last)

(First)

(Middle)

9001 LIBERTY PARKWAY

(Street)

BIRMINGHAM

ALABAMA

35242

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Encompass Health Corp [ EHC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Encompass Health Common Stock	04/15/2026		A		19⁽¹⁾	A	$0	15,469	D
Encompass Health Common Stock	04/16/2026		A		334⁽²⁾	A	$106.48⁽³⁾	15,803	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments, The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On April 15, 2026, Encompass Health paid a dividend on its common stock of $0.19 per share and the closing price was $105.24. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

2. The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2025 to defer fixed percentages of their director fees for 2026. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the director's fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. The number reported represents shares purchased with the quarterly fee deferral and the dividend of $0.19 per share paid on April 15, 2026.

3. This per share price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $106.21 to $106.48, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.

	/s/ Patrick Darby, attorney-in-fact for Christopher R. Reidy	04/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Encompass Health (EHC) director Christopher Reidy report in this Form 4?

Christopher Reidy reported acquiring additional Encompass Health Common Stock through equity awards and a deferred fee plan. He received 334 shares at a weighted average price of $106.48 and 19 shares at $0.00, bringing his direct holdings to 15,803 shares.

How many Encompass Health (EHC) shares did Christopher Reidy acquire and at what prices?

Reidy acquired 334 shares of Encompass Health Common Stock at a weighted average price of $106.48 and 19 shares at $0.00. These acquisitions reflect a director equity award and shares from a deferred fee and dividend reinvestment plan, not an open-market purchase.

How does the Directors Deferred Stock Investment Plan affect Encompass Health (EHC) director holdings?

The Directors Deferred Stock Investment Plan lets non-employee directors defer portions of their fees to buy Encompass Health stock in the market. Those shares receive cash dividends, which are reinvested into more company stock, gradually increasing each participating director’s ownership position over time.

Are Christopher Reidy’s reported Encompass Health (EHC) transactions open-market buys?

The transactions are classified as grant or award acquisitions, not open-market purchases. Shares and restricted stock units were credited under director compensation and deferral arrangements and through dividend reinvestment, according to the plan terms and disclosed pricing mechanics.